May 13, 2019

Richard Pazdur, MD, Director  
FDA Oncology Center of Excellence  
Attn: Docket Management Staff (HFA-305)  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

Submitted via https://www.regulations.gov

SUBJECT: FDA Draft Guidance for Industry on Cancer Clinical Trial Eligibility Criteria: Brain Metastases

Dear Dr. Pazdur:

On behalf of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), we appreciate the opportunity to comment on the recently released FDA Draft Guidance for Industry on Cancer Clinical Trial Eligibility Criteria: Brain Metastases.

Overall, we find the draft guidance reasonable and agree it balances concerns regarding inclusion and exclusion criteria for patients with brain metastases for clinical trials of systemically administered investigational therapies. We understand the need for the guidance to be rather general, given the broad clinical spectrum encompassed by the term “brain metastases.” However, we are concerned that companies may find some of the terms in the draft guidance indistinct.

For example, the definition of a stable tumor raises several questions, some of which are listed below:

1. How long do lesions need to be unchanged to be stable?
2. Is the definition of stable disease restricted to a stable enhancing mass?
3. Is stable edema a criterion for stable disease?
4. Do clinical symptoms need to be stable? If so, for how long?

For stable corticosteroid use, we appreciate efforts to try to delineate a time frame, but we question whether one week is long enough to assume stability. A time window of two to four weeks is probably more clinically relevant.

Also, we believe there may be some lack of clarity for the definition of active disease. Which of the following would be important in assessing whether the disease is active?

1. Asymptomatic radiographic progression?
2. Symptomatic radiographic progression with clinical symptoms controlled by corticosteroids?
3. Symptomatic progression uncontrolled by corticosteroids?
4. Symptomatic progression with enlarging enhancing tumor?
5. Symptomatic progression with enlarging edema?
6. Symptomatic progression with enlarging enhancing tumor and edema?

The suggestions for having a separate cohort, limited numbers, separate subset analyses and stratification in randomized studies are all good ideas. However, the clinical investigators managing the studies must weigh the value of including these items against the cost of enrolling additional patients.

In the section discussing Investigational Drugs (lines 160-163), we recommend the reference to “Central Nervous System (CNS) penetration” be modified to say “brain tumor and/or CNS penetration.” We want to emphasize that drug penetration into an enhancing brain tumor does not necessarily indicate penetration into the CNS, where even in the case of brain metastases there may be microscopic disease surrounding the tumor mass that does not result in contrast enhancement.

For your information, we have enclosed a copy of the recently published Congress of Neurological Surgeons (CNS) Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults with Metastatic Brain Tumors.

Thank you for considering our comments. Please let us know if we can provide any additional information.

Sincerely,

Christopher I. Shaffrey, President
American Association of Neurological Surgeons

Ganesh Rao, MD, President
Congress of Neurological Surgeons

Enclosure
- Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines of Surgery in the Management of Adults with Metastatic Brain Tumors

Staff Contact:
Catherine Jeakle Hill
Senior Manager, Regulatory Affairs
AANS/CNS Washington Office
25 Massachusetts Avenue, NW, Suite 610
Washington, DC  20001
Phone:  202-446-2026
E-mail:  chill@neurosurgery.org
CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINES FOR THE TREATMENT OF ADULTS WITH METASTATIC BRAIN TUMORS: INTRODUCTION AND METHODS

Sponsored by
The Congress of Neurological Surgeons and the Section on Tumors

Affirmation of Educational Benefit by
The Congress of Neurological Surgeons and the American Association of Neurological Surgeons

Jeffrey J. Olson, MD,1 Steven N. Kalkanis, MD,2 and Timothy C. Ryken, MD, MS3

1. Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia
2. Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan
3. Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Correspondence:
Jeffrey J. Olson, MD
Department of Neurosurgery
Emory University School of Medicine
1365B Clifton Road, NE,
Atlanta, GA 30322
E-mail: jolson@emory.edu

ABSTRACT

Background: The Congress of Neurological Surgeons systematic review and evidence-based clinical practice parameter guidelines for the treatment of adults with metastatic brain tumors was first published in 2010. Based upon the time elapsed since that publication, an update of this set of guidelines based upon literature published since is now indicated.

Objectives: The objective of these guidelines was to establish the best evidence-based management of metastatic brain tumors over all commonly used diagnostic and treatment modalities in regularly encountered clinical situations.

Methods: Literature searches regarding the management of metastatic brain tumors with whole brain radiation therapy, surgery, stereotactic radiosurgery, chemotherapy, prophylactic anticonvulsants, steroids, instances of multiple brain metastases, and emerging and investigational therapies were carried out to answer questions designed by consensus of a multidisciplinary writing group.

Results: Recommendations were created and their strength linked to the quality of the literature data available thus creating an evidence-based guideline. Importantly, shortcomings and biases to the literature data are addressed to provide guidance for future investigation and improvements in the...
management of metastatic brain tumors.

Conclusions: This series of guidelines was constructed to assess the most current and clinically relevant evidence for management of metastatic brain tumors. They set a benchmark regarding the current evidence base for this management while also highlighting important key areas for future basic and clinical research, particularly on those topics for which no recommendations could be formulated.

INTRODUCTION

Background and Rationale

Guidelines on the management of metastatic brain tumors were published in 2010 and endorsed by the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS). A component of that set of guidelines was recognition that updates would eventually be necessary so as to allow the recommendations to be modified to stay abreast of advances in the care and management of metastatic brain tumors. This updated set of guidelines has been created in response to that recognition.

Although there are data to show that it is declining in incidence, cancer remains an important health problem as it is estimated there were more than 1.6 million new cancer cases in the United States in 2015. Although there a number of ways of measuring it, the estimated prevalence of new brain metastases in the United States is between 7 and 14 persons per 100,000 based on population studies. On the basis of an official census of nearly 310 million people in the United States, the expected incidence of newly diagnosed patients with brain metastases is estimated to be between 21,651 and 43,301 annually. Metastases from lung, breast, and melanoma primary tumors make up the bulk of the lesions identified. The reasons for this increase in incidence cannot be discerned exactly but is probably due to a combination of improved imaging, an increase in the prevalence of cancers prone to metastasize to the brain, and improved survival of patients with cancer. Between 1983 and 2009, Nieder et al. reported a decline in the incidence of lung cancer brain metastases, and an increase in the incidence of melanoma, colorectal, and kidney brain metastases, as well as the relative stability in the incidence of breast cancer brain metastases cases.

These guidelines include sections similar to those previously published, including topics such as surgery, radiation and chemotherapy. Additionally, the task force concluded that there would be value in adding sections on the management of multiple metastases and radiation necrosis.

The methods and style used here are adapted from and similar to other guidelines projects endorsed by the AANS and CNS. This coherence and repetitive nature is intentionally used for the purposes of reproducibility and streamlining the administration of their creation. Each section was developed with recognition of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist items. The manner in which these points are addressed varies by section depending on the nature of the information available.

By way of definition, this systematic review and subsequent set of guidelines defines brain metastases as solid metastases to the brain from systemic cancer. The definition excludes leptomeningeal metastatic disease.

Objectives and Guideline Panel Development

Recognizing the important health impact of metastatic brain tumors along with the lack of consensus among various treatment options, the Joint Tumor Section recommended that evidence-based guidelines be developed as a top priority, for the diagnosis, management, and treatment of patients with metastatic brain tumors. The objectives of these guidelines are to establish the best evidence-
based management of metastatic brain tumors in terms of whole brain radiation therapy, surgery, stereotactic radiosurgery, chemotherapy, prophylactic anticonvulsants, steroids, and instances of multiple brain metastases. Because the management of these tumors remains imperfect, it was also recommended that information on promising emerging therapies be assessed in the same manner to determine the possible application of these findings.

Having identified the topical objectives, the Guidelines Committee of the Joint Tumor Section then recruited experts in the field from each of the parent organizations as lead authors of each section (Table 1). These authors, in turn, recruited experts in non-neurosurgical specialties relevant to the field of management and therapy chosen. The authors were provided with training on the method of guideline development as used in this guideline set, using stepwise written instructions and then providing direct guidance as needed for each writer. The senior authors and CNS Guidelines Manager then worked with them on a step-by-step basis to confirm that the methods were followed as the literature was collected and assessed, and the documents were developed. When the authors were approached and preliminarily agreed to participate, they were asked to complete a formal conflict of interest (COI) questionnaire confirming the appropriateness of their participation. The authors also agreed to report any new conflicts of interest that might develop during the writing process. In this manner, a multidisciplinary panel of authors referred to as the Metastatic Brain Tumor Guidelines Task Force was assembled (with significant administrative, logistical, and analytical support from the CNS Guidelines Committee). The method of this evidence-based clinical practice parameter guideline has been written in a manner to be as transparent as possible using published assessment criteria.

METHODS

Topic Range of this Systematic Review and Evidence-Based Clinical Practice Guideline

Having identified authors for each topic, the members assessed the questions from the previously published guidelines. They either kept them as they were or in some cases modified and updated them, and also added additional questions to allow for assessment of the literature in a manner that would provide guidance for the management of metastatic brain tumors. These questions are presented at the beginning of each of the eight guideline chapters spanning the topics of whole brain radiation therapy, surgical resection, stereotactic radiosurgery, chemotherapy, prophylactic anticonvulsants, steroid use, management of multiple brain metastases, and emerging and investigational therapies. The questions developed for each section are summarized in Table 2.

Literature Examination Approach

A wide-ranging literature search strategy was undertaken to identify all citations relevant to the management of metastatic brain tumors. The MEDLINE (utilizing the PubMed or Ovid interface) and Embase® electronic databases were searched with additional data being gleaned from the Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials. The date range was from October 2008 through December 2015 for questions that were unchanged from the guidelines published in 2010. For new questions or questions modified significantly from the 2010 publication, the date range for the searches was chosen as January 1990 through December 2015. Additionally, important articles from before this interval were reviewed and included if deemed to be critical evidence by the task force. The search strategies used a combination of controlled vocabulary terms and text words. The specifics of the searches for a given topic are outlined in each respective guideline section. Reference lists of the publications chosen for full-text review were also screened for potentially relevant studies.

Study Selection, Quality Assessment and Statistical Methods
The search of the bibliographic databases identified possibly relevant citations for a given topic and often these were large in number. The eligibility (inclusion/exclusion) criteria to screen the citations for each of the questions were determined ahead of time for each section by the respective writing group. These are documented in the individual clinical practice guideline sections in this series to assist the reader in understanding the development process. At least two authors evaluated the titles and abstracts using the inclusion and exclusion criteria with broad interpretation of the criteria being used initially so as to maximize the likelihood of capturing pertinent information. Cases of disagreement about pertinence were resolved by a third author when needed. The full-text articles of the selected abstracts were then collected and the same process of applying the eligibility criteria was carried out again with the more detailed information available in the manuscripts. Articles that met the eligibility criteria were grouped according to the questions they addressed and used to create the evidence tables and results sections. Reasons for exclusion for papers were also documented to be able to discuss pertinent problem citations in the results sections as needed.

Studies that met the eligibility criteria were subject to more detailed scrutiny. Their data were extracted by one reviewer and the extracted information was checked by one or more other reviewers. Evidence tables, reporting the extracted study information and evidence classification, were generated for all of the included studies. Evidence tables were created with the most recent data first and subsequent listings in retrograde chronological order. The table headings consisted of first author name and year, followed by a brief study description, chosen data class, and conclusion. The authors were directed to craft the data in the tables in a succinct and fact-filled manner to allow for rapid understanding of the literature entry by the readership. The literature in the evidence tables was expanded upon in the results section of each section to emphasize important points supporting its classification and contribution to recommendations. Additional information about the methods used in this systematic review can be found at https://www.cns.org/guidelines/guideline-procedures-policies/guideline-development-methodology.

Internal drafts of the tables and manuscripts were developed by sharing them between authors electronically, by telephone, and in person meetings. Summary and conclusion statements were included for each section, with comments on key issues for future investigation being added where pertinent. When adequate data were presented in the manuscripts, the authors made an effort to measure the agreement between observations or observers beyond chance using the kappa statistic.

AANS/CNS Evidence Classes and Levels of Recommendations

The evidence classifications were then used to create recommendations, the strength of which were graded according to the Joint Guidelines Review Committee (JGRC) Guideline Development Methodology (Tables 3-6). The class of evidence assigned to each study was based on study design (ie, Class I, II, or III). The strength of the recommendations made (ie, Level 1, 2, or 3) was directly linked to the evidence classification and took into account aspects of study quality and whether or not the plan was accomplished, not just study design. To restate, Class I evidence could be extrapolated to Level 1 recommendations or lower, Class II evidence could be extrapolated to Level 2 evidence or lower, and Class III evidence could only yield Level 3 recommendations. Specifically, the level of a recommendation made could be decreased, based on consensus input by the writing group, if there were methodological concerns regarding the studies that provided evidence for that particular recommendation. Additional information about the methods used in this systematic review can be found at https://www.cns.org/guidelines/guideline-procedures-policies/guideline-development-methodology.
Guideline Panel Consensus and Approval Process

As previously mentioned, a multidisciplinary task force was created for each section based on author expertise to address each of the disciplines and particular areas of therapy selected for these clinical guidelines. Each group was involved with literature selection, creation and editing of the evidence tables and results for their specific section and discipline. Using this information, the task force then drafted the recommendations in response to the questions formulated at the beginning of the process, culminating in the clinical practice guideline for their respective discipline. The draft guidelines were then circulated to the entire task force to allow for multidisciplinary feedback, discussion, and ultimately approval.

Two topics originally identified for consideration in this set of guidelines documents were eventually removed from consideration and further development. In the previous set of guidelines published in 2010, there was a section on retreatment,\(^6\) that included 2 questions. This resulted in 1 Class III recommendation for the first question, which stated that treatment should be individualized using whatever modality is deemed appropriate by the treating clinician. No recommendation could be formulated for the second question. A literature search to address 3 updated questions for retreatment of metastatic brain tumors was mounted for this update. A total of 1739 citations were generated, of which 44 were deemed worthy of full-text review. It was concluded that no meaningful new guidance could be provided for retreatment of metastatic brain tumors. Because the previous publication on retreatment provided the lowest level or no recommendations on that topic, the task force chose to not include a section on this topic in this iteration of the metastatic brain tumor management guidelines. In the other sections of this set of guidelines, some data were found to support comments on treatment of recurrent metastatic brain tumors. The readers are referred to them for elaboration.

Additionally, there was a planned section on management of radiation necrosis. A literature search to address 5 questions was mounted. This resulted in 1253 unique citations. Review of these resulted in the realization that there is not a broadly accepted definition of radiation necrosis in this disease setting, and there was no properly designed clinical research available beyond simple case series to make concrete and declarative recommendations. Based on these findings, this section was abandoned.

The completed evidence-based clinical practice guidelines for the management of metastatic brain tumors were presented to the JGRC of the AANS/CNS for peer review. The reviewers for the JGRC were vetted by Neurosurgery for suitability and expertise to serve as reviewers for the purposes of publication in that journal. The final product was then approved and endorsed by the executive committees of both the AANS and CNS prior to publication in Neurosurgery.

Figure 1 provides an outline of the key steps in the process of developing these clinical practice guidelines.

DISCUSSION

This series of guidelines was constructed to assess the most current and clinically relevant evidence for the management of metastatic brain tumors in order to set a benchmark for standard of care while also highlighting important key areas for future research. Only by designing future investigations in a high-quality manner that recognizes and overcomes prior weaknesses noted in these guidelines will advancement toward a remedy of this disease be achieved. Secondarily, the suggestions provided are set forth for conscientious use by the practicing physician who must take into account all of the unique individual conditions in the therapy of a given person during his or her illness. The application of published guidelines information is an activity that results in strong and often polarizing opinions. The
guidelines presented in this current project are not meant to resolve these issues, and it is unlikely that any could accomplish such a goal. Fortunately, new research is constantly underway, and these guidelines are meant to be improved as this new evidence matures and is published. One will note that the PRISMA checklist serves as a forerunner to the 2011 Institute of Medicine Clinical Practice Guideline Development Process. An important part of that document, called Standard 8, suggests timely updating the data and recommendations. To that point, the data analyzed for this set of guidelines has been collected through 2015. It is estimated that the updated iteration of this guideline overall will be written in approximately 5 years with modification of this timeline dependent on emergence of important scientific and therapeutic advances.

Potential Conflicts of Interest

The Brain Metastases Guideline Update Task Force members were required to report all possible conflicts of interest (COIs) prior to beginning work on the guideline, using the COI disclosure form of the AANS/CNS Joint Guidelines Review Committee, including potential COIs that are unrelated to the topic of the guideline. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination. The CNS Guidelines Committee and Guideline Task Force Chair are given latitude to approve nominations of task force members with possible conflicts and address this by restricting the writing and reviewing privileges of that person to topics unrelated to the possible COIs. The conflict of interest findings are provided in detail in Table 7.

Disclosures

These evidence-based clinical practice guidelines were funded exclusively by the Congress of Neurological Surgeons and the Tumor Section of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons, which received no funding from outside commercial sources to support the development of this document.

Disclaimer of Liability

This clinical systematic review and evidence-based guideline was developed by a multidisciplinary physician volunteer task force and serves as an educational tool designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient’s physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.

Acknowledgments

The authors acknowledge the CNS Guidelines Committee for its contributions throughout the development of the guideline and the AANS/CNS Joint Guidelines Review Committee for its review, comments, and suggestions throughout peer review, as well as Trish Rehring, MPH, CHES, CNS Guidelines Senior Manager, and Mary Bodach, MLIS, Senior Guidelines Specialist, for their assistance. Throughout the review process, the reviewers and authors were blinded from one another. At this time, the guidelines task force would like to acknowledge the following individual peer reviewers for their contributions: Manish Aghi, MD, PhD, Manmeet Ahuwalia, MD, Sepideh Amin-Hanjani, MD, Edward Avila, MD, Maya Babu, MD, MBA, Kimon Bekelis, MD, Priscilla Brastianos, MD, Paul Brown,
Table 1. Metastatic Brain Tumor Guidelines Authors

<table>
<thead>
<tr>
<th>Guideline Author</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Alvarez-Breckenridge, MD, PhD</td>
<td>Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts</td>
</tr>
<tr>
<td>Mario Ammirati, MD, MBA</td>
<td>Department of Neurosurgery, St. Rita Medical Center, Lima, Ohio</td>
</tr>
<tr>
<td>David W. Andrews, MD</td>
<td>Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>Priscilla K. Brastianos, MD</td>
<td>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</td>
</tr>
<tr>
<td>Clark C. Chen, MD, PhD</td>
<td>Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, Minnesota</td>
</tr>
<tr>
<td>Charles S. Cobbs, MD</td>
<td>Department of Neurosurgery, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington</td>
</tr>
<tr>
<td>J. Bradley Elder, MD</td>
<td>Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio</td>
</tr>
<tr>
<td>Laurie E. Gaspar, MD, MBA</td>
<td>Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado</td>
</tr>
<tr>
<td>Jerome J. Graber, MD, MPH</td>
<td>Department of Neurology, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington</td>
</tr>
<tr>
<td>Alia Hdeib, MD</td>
<td>Department of Neurosurgery, Case Western Reserve University</td>
</tr>
<tr>
<td>Steven N. Kalkanis, MD</td>
<td>Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan</td>
</tr>
<tr>
<td>John S. Kuo, MD, PhD</td>
<td>Department of Neurosurgery and Mulva Clinic for the Neurosciences, Dell Medical School, University of Texas at Austin, Austin, Texas</td>
</tr>
<tr>
<td>George F. Lasker, MD, PhD</td>
<td>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California</td>
</tr>
<tr>
<td>Mark E. Linskey, MD</td>
<td>Department of Surgery, University of California, Irvine, Orange, California</td>
</tr>
</tbody>
</table>
Table 2. Questions Addressed in this Guideline

<table>
<thead>
<tr>
<th>Guideline Topic</th>
<th>Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Brain Radiation Therapy</td>
<td>If WBRT is used, is there an optimal dose/fractionation schedule?</td>
</tr>
<tr>
<td>Guideline Topic</td>
<td>Questions</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>What impact does tumor histopathology or molecular status have on the decision to use WBRT, the dose fractionation scheme to be utilized, and its outcomes?</td>
</tr>
<tr>
<td></td>
<td>Separate from survival outcomes, what are the neurocognitive consequences of WBRT, and what steps can be taken to minimize them?</td>
</tr>
<tr>
<td></td>
<td>Does the addition of WBRT after surgical resection or radiosurgery improve progression-free or overall survival outcomes when compared to surgical resection or radiosurgery alone?</td>
</tr>
<tr>
<td>Surgical Resection</td>
<td>Should patients with newly diagnosed metastatic brain tumors undergo surgery, SRS, or WBRT?</td>
</tr>
<tr>
<td></td>
<td>Should patients with newly diagnosed metastatic brain tumors undergo surgical resection followed by WBRT, SRS, or another combination of these modalities?</td>
</tr>
<tr>
<td></td>
<td>Should patients with recurrent metastatic brain tumors undergo surgical resection?</td>
</tr>
<tr>
<td></td>
<td>Does the surgical technique (en bloc resection or piecemeal resection) affect recurrence?</td>
</tr>
<tr>
<td></td>
<td>Does the extent of surgical resection (gross total resection or subtotal resection) affect recurrence?</td>
</tr>
<tr>
<td>Stereotactic Radiosurgery</td>
<td>Should patients with newly diagnosed metastatic brain tumors undergo SRS compared with other treatment modalities?</td>
</tr>
<tr>
<td></td>
<td>What is the role of SRS after open surgical resection of brain metastasis?</td>
</tr>
<tr>
<td>Guideline Topic</td>
<td>Questions</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td>Should patients with brain metastases receive chemotherapy in addition to WBRT for the treatment of their brain metastases?</td>
</tr>
<tr>
<td></td>
<td>Should patients with brain metastases receive chemotherapy in addition to SRS for the treatment of their brain metastases?</td>
</tr>
<tr>
<td></td>
<td>Should patients with brain metastases receive chemotherapy alone?</td>
</tr>
<tr>
<td><strong>Prophylactic Anticonvulsants</strong></td>
<td>Do prophylactic AEDs decrease the risk of seizures in non-surgical patients with brain metastases who are otherwise seizure free?</td>
</tr>
<tr>
<td></td>
<td>Do prophylactic AEDs decrease the risk of seizures in patients with brain metastases and no prior history of seizures in the postoperative setting?</td>
</tr>
<tr>
<td><strong>Steroids</strong></td>
<td>Do steroids improve neurologic symptoms and/or quality of life in patients with metastatic brain tumors compared to supportive care only or other treatment options?</td>
</tr>
<tr>
<td></td>
<td>If steroids are given, what dose should be used?</td>
</tr>
<tr>
<td><strong>Emerging Therapy</strong></td>
<td></td>
</tr>
<tr>
<td>Guideline Topic</td>
<td>Questions</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td>What evidence is available regarding emerging and investigational treatment options for metastatic brain tumors?</td>
</tr>
<tr>
<td></td>
<td>High Intensity Focused Ultrasound</td>
</tr>
<tr>
<td></td>
<td>Laser Interstitial Thermal Therapy</td>
</tr>
<tr>
<td></td>
<td>Radiation sensitizers</td>
</tr>
<tr>
<td></td>
<td>Interstitial modalities</td>
</tr>
<tr>
<td></td>
<td>Immune modulators</td>
</tr>
<tr>
<td></td>
<td>Molecular targeted agents</td>
</tr>
</tbody>
</table>

**Multiple Metastases**

|                 | In what circumstances should WBRT be recommended to improve tumor control and survival in patients with multiple brain metastases? |
|                 | In what circumstances should SRS be recommended to improve tumor control and survival in patients with multiple brain metastases? |
|                 | In what circumstances should surgery be recommended to improve tumor control and survival in patients with multiple brain metastases? |

*AED*, Antiepileptic drug; *SRS*, stereotactic radiosurgery; *WBRT*, whole brain radiation therapy.

**Table 3. AANS/CNS Classification of Evidence on Therapeutic Effectiveness and Levels of Recommendation**

**Evidence Classification**

- **Class I** Evidence provided by one or more well-designed randomized controlled clinical trials, including overview (meta-analyses) of such trials
- **Class II** Evidence provided by well-designed observational studies with concurrent controls (eg case-control and cohort studies)
- **Class III** Evidence provided by expert opinion, case series, case reports and studies with historical controls

**Levels of Recommendation**
Level 1
Generally accepted principles for patient management, which reflect a high degree of clinical certainty (usually this requires Class I evidence which directly addresses the clinical questions or overwhelming Class II evidence when circumstances preclude randomized clinical trials)

Level 2
Recommendations for patient management which reflect clinical certainty (usually this requires Class II evidence or a strong consensus of class III evidence)

Level 3
Other strategies for patient management for which the clinical utility is uncertain (inconclusive or conflicting evidence or opinion)

Table 4. AANS/CNS Classification of Evidence on Diagnosis and Levels of Recommendation

<table>
<thead>
<tr>
<th>Class I Evidence</th>
<th>Level 1 Recommendation</th>
</tr>
</thead>
</table>
| Evidence provided by one or more well-designed clinical studies of a *diverse* population using a "gold standard" reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios.

<table>
<thead>
<tr>
<th>Class II Evidence</th>
<th>Level 2 Recommendation</th>
</tr>
</thead>
</table>
| Evidence provided by one or more well-designed clinical studies of a *restricted* population using a "gold standard" reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios.

<table>
<thead>
<tr>
<th>Class III Evidence</th>
<th>Level 3 Recommendation</th>
</tr>
</thead>
</table>
| Evidence provided by expert opinion or studies that do not meet the criteria for the delineation of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios.

Table 5. AANS/CNS Classification of Evidence on Clinical Assessment and Levels of Recommendation

<table>
<thead>
<tr>
<th>Class I Evidence</th>
<th>Level 1 Recommendation</th>
</tr>
</thead>
</table>
| Evidence provided by one or more well-designed clinical studies in which interobserver and/or intraobserver reliability is represented by a **Kappa statistic >0.60**.

<table>
<thead>
<tr>
<th>Class II Evidence</th>
<th>Level 2 Recommendation</th>
</tr>
</thead>
</table>
| Evidence provided by one or more well-designed clinical studies in which interobserver and/or intraobserver reliability is represented by a **Kappa statistic >0.40**.
Class III Evidence  
Level 3 Recommendation  
Evidence provided by one or more well-designed clinical studies in which interobserver and/or intraobserver reliability is represented by a Kappa statistic <0.40.

Table 6. AANS/CNS Classification of Evidence on Prognosis and Levels of Recommendation

In order to evaluate papers addressing prognosis, five technical criteria are applied:

- Was a well-defined representative sample of patients assembled at a common (usually early) point in the course of their disease?
- Was patient follow-up sufficiently long and complete?
- Were objective outcome criteria applied in a "blinded" fashion?
- If subgroups with different prognoses were identified, was there adjustment for important prognostic factors?
- If specific prognostic factors were identified, was there validation in an independent “test set” group of patients?

Class I Evidence  
Level 1 Recommendation  
All 5 technical criteria above are satisfied.

Class II Evidence  
Level 2 Recommendation  
Four of 5 technical criteria are satisfied.

Class III Evidence  
Level 3 Recommendation  
Everything else.

Table 7. COI Disclosures

<table>
<thead>
<tr>
<th>Guideline Authors</th>
<th>Potential COI</th>
</tr>
</thead>
<tbody>
<tr>
<td>David W. Andrews, MD</td>
<td>1. Brainlab: Consultant fee</td>
</tr>
<tr>
<td></td>
<td>2. IMVAX: Stock shareholder</td>
</tr>
<tr>
<td></td>
<td>3. IMVAX: Board/Trustee/Officer position (CEO)</td>
</tr>
<tr>
<td>Priscilla K. Brastianos, MD</td>
<td>1. Genentech: Consultant fee</td>
</tr>
<tr>
<td></td>
<td>2. Roche: Consultant fee</td>
</tr>
<tr>
<td></td>
<td>3. Angiochem: Consultant fee</td>
</tr>
<tr>
<td></td>
<td>4. Merck: Honorarium</td>
</tr>
</tbody>
</table>
Figure 1. An outline of the key steps in the process of developing these clinical practice guidelines
AANS/CNS Joint Tumor Section decides to develop evidence-based guidelines on the management of metastatic brain tumors

Formation of the clinical expert guideline panel

Topic Refinement:
Scope of questions to be addressed and establishment of literature eligibility

Literature search, study selection, data extraction, quality assessment, and creation of evidence tables

Writing groups formulate draft clinical practice guidelines

Circulation of the draft guidelines to entire guideline panel for feedback, discussion, and consensus

Draft guidelines presented to the JGRC for review

Edits and revisions from JGRC addressed/resolved and edits incorporated into the draft

AANS Board, CNS Executive Committee, and AANS/CNS Joint Tumor Section Executive Committee review the guidelines for endorsement decision

Submission of the guidelines to Neurosurgery for publication

AANS: American Association of Neurological Surgeons; CNS: Congress of Neurological Surgeons; JGRC: Joint Guidelines Review Committee

REFERENCES


Source:
*Neurosurgery, January 9, 2019* ([https://doi.org/10.1093/neuros/nyy540](https://doi.org/10.1093/neuros/nyy540))

Download the pdf:

brain_mets_intro_methods.pdf